

Robert Embree and Jason Allchin Team Up to Start EmeritusDX

Highly Accomplished Leaders within the Healthcare Industry Start Diagnostic Company in Pursuit of Uncompromising Patient Care

NEWS PROVIDED BY

EmeritusDX

Jan 20, 2021, 16:00 ET

The logo for EmeritusDX, with "Emeritus" in blue and "DX" in green.

COSTA MESA, Calif., Jan. 20, 2021 /PRNewswire-PRWeb/ -- Today Robert Embree and Jason Allchin announced they would be forming EmeritusDX, a cancer diagnostics company located in Southern California. With a focus on oncology, their Anatomic Pathology and FISH laboratories will provide diagnostic services as well as research testing for the development of nextgen tests and therapies.

Mr. Embree is an experienced executive with over 30 years of leadership within the healthcare and laboratory industry. He has held numerous executive roles and was most recently co-founder and Executive Vice President of Operations at Pathnostics. "Our common purpose is to save lives one specimen at a time. We accomplish this by solving the medical, scientific, and logistical dilemmas that impede delivering the best patient care."

Our common purpose is to save lives, one specimen at a time.

 Post this



Mr. Allchin has a strong track record of building and growing businesses during a distinguished career spanning over 20 years in healthcare. He has led healthcare service companies ranging in size from \$35 million to \$500 million in revenue and was most recently the Vice President of Operations for NeoGenomics. "We are driven to improve the outcome for cancer patients through our diagnostic service, as well as the test and drug development we perform with our partners."

About EmeritusDX

EmeritusDX is a cancer diagnostics company that is driven by our obsession to continuously improve patient care. Within our CLIA certified laboratory, our expertise is in delivering diagnostic laboratory services as well as effectively supporting the custom research and clinical trial markets. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email cs@emeritusdx.com

Media Contact

Jason Allchin, EmeritusDX, +1 800-959-2846, jallchin@emeritusdx.com

SOURCE EmeritusDX

Related Links

<http://www.emeritusdx.com>